Andrew Lytle

Dec 11, 2023 | brnw.ch | Alan Cooper |Andrew Lytle |Brendan P. Hodkinson |Kyle Kissick

CONTEXTKey ObjectiveTo determine if a novel CD5 gene expression signature accurately captures diffuse large B-cell lymphomas (DLBCLs) vulnerable to Bruton's tyrosine kinase inhibitor–based therapy in DLBCL. Knowledge GeneratedCD5 immunohistochemistry and a novel CD5 gene expression signature (CD5sig) capture DLBCLs with both genetic and nongenetic bases for B-cell receptor (BCR) dependence.

Dec 11, 2023 | ascopubs.org | Alan Cooper |Kyle Kissick |Andrew Lytle |Brendan P. Hodkinson

Authors retain all rights in any data supplements associated with their articlesThe ideas and opinions expressed in these Data Supplements do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in these Data Supplements should not be construed as an endorsement of the products mentioned.